GSK (LON:GSK) Rating Reiterated by Deutsche Bank Aktiengesellschaft

GSK (LON:GSK)‘s stock had its “buy” rating restated by equities research analysts at Deutsche Bank Aktiengesellschaft in a research note issued to investors on Wednesday, Marketbeat reports. They presently have a GBX 1,950 ($24.27) target price on the stock. Deutsche Bank Aktiengesellschaft’s target price points to a potential upside of 23.14% from the stock’s previous close.

GSK has been the topic of several other research reports. Shore Capital reissued a “buy” rating on shares of GSK in a report on Thursday, March 7th. Barclays reaffirmed an “equal weight” rating and set a GBX 1,725 ($21.47) price objective on shares of GSK in a report on Monday, April 8th. Finally, Berenberg Bank boosted their price target on shares of GSK from GBX 1,650 ($20.54) to GBX 1,820 ($22.66) and gave the stock a “buy” rating in a research report on Wednesday, February 14th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of GBX 1,630.63 ($20.30).

GSK Stock Down 0.4 %

Shares of GSK stock opened at GBX 1,583.50 ($19.71) on Wednesday. The company has a debt-to-equity ratio of 140.82, a current ratio of 0.88 and a quick ratio of 0.73. GSK has a one year low of GBX 1,302.60 ($16.22) and a one year high of GBX 1,719.80 ($21.41). The company’s fifty day moving average price is GBX 1,662.39 and its 200-day moving average price is GBX 1,545.33. The company has a market capitalization of £64.77 billion, a price-to-earnings ratio of 1,319.58, a PEG ratio of 1.09 and a beta of 0.27.

Insider Buying and Selling

In other news, insider Emma Walmsley sold 139,792 shares of the business’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of GBX 1,658 ($20.64), for a total value of £2,317,751.36 ($2,885,287.39). In other news, insider Emma Walmsley sold 139,792 shares of the firm’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of GBX 1,658 ($20.64), for a total value of £2,317,751.36 ($2,885,287.39). Also, insider Urs Rohner acquired 434 shares of GSK stock in a transaction that occurred on Wednesday, March 20th. The shares were purchased at an average price of GBX 1,662 ($20.69) per share, with a total value of £7,213.08 ($8,979.31). Insiders acquired 19,802 shares of company stock valued at $31,381,484 over the last 90 days. Corporate insiders own 1.71% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.